BioSpace News Archive

Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”) is pleased to announce that further to its press releases of August 31, 2023, September 22, 2023, October 5, 2023

As part of the U.S. Food and Drug Administration’s commitment to protecting public health, the agency is advising the public, including healthcare providers, of the possible risks that products containing live bacteria or yeast, which are commonly called probiotics, pose to preterm infants in hospital settings.

Fore Genomics, Inc. announced the launch of its revolutionary FORESITE 360™ service using whole genome sequencing , which gives you a complete map of your baby’s DNA with a simple at-home collection kit.

Woebot Health today announced positive results from a study at Children’s Hospital of The King’s Daughters (CHKD) showing that the digital mental health intervention W-GenZD, a Woebot-based study app, led to reductions in depressive symptoms that were non-inferior to those achieved by a clinician-led telehealth Cognitive Behavioral Therapy (CBT) skills group.

Edwards Lifesciences Corporation announced successful results from TRISCEND II, a randomized controlled pivotal trial designed to evaluate the safety and effectiveness of the groundbreaking EVOQUE tricuspid valve replacement system with optimal medical therapy compared to OMT alone with 2:1 randomization.

Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced today 510(k) clearance of its new 3D-printed tibial implants, the Vantage® Ankle 3D and 3D+.

Moderna, Inc. announced it was ranked as one of the top employers in the global biopharmaceutical industry in Science and Science Careers’ 2023 Top Employers Survey for the ninth consecutive year.

Edwards Lifesciences Corporation announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two contemporary mitral transcatheter edge-to-edge repair therapies, as well as one-year results from the CLASP IID registry.

Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX) today reported that Santhera Pharmaceuticals (“Santhera”) has obtained U.S. Food and Drug Administration (“FDA”) approval for AGAMREE® (vamorolone) oral suspension 40 mg/mL for use in treating Duchenne Muscular Dystrophy (“DMD”) in patients aged two years and older.

October 26, 2023. Novozymes delivers 5% organic sales growth, an EBIT-margin of 25.5% before special items, and ROIC including goodwill of 16.3% before special items in the first nine months of the 2023 financial year.